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A sunscreen is labelled with its sun protection factor (SPF). This
is a measure of the protection it a¡ords against sunburn after a
single exposure of solar simulating radiation (SSR): nothing
more and nothing less. Calculations based on the action spectrum
(wavelength dependence) for erythema (sunburn) and solar emis-
sion spectra show that the small UVB (B5%) component of
solar UVR accounts for the vast majority (480%) of its erythe-
mal e¡ect. Thus, sunscreens cannot work without attenuating
UVB. In recent years, especially in Europe, there has been a trend
towards broad-spectrum sunscreens with good UVA protection.
A standard method of de¢ning UVA protection has yet to be
agreed and there is still controversy about the merits of UVA
protection.
The attenuation of UVB by sunscreen use is widely advocated
to reduce skin cancer risk and the consumer has the right to
know if such advice is evidence-based. In reality, it is largely
based on mouse studies and molecular epidemiology which sug-
gest that UVB is much more important than UVA, at least for
non-melanoma skin cancer. There is only limited epidemiological
evidence that sunscreen use inhibits actinic keratoses and squa-
mous cell carcinoma but no evidence that sunscreens have any
e¡ect in the prevention of basal cell carcinoma or malignant mel-
anoma (IARC). The reasons that sunscreens may fail to inhibit
skin cancer are too complex to be reviewed here, but may include
their immunoprotective properties because UVR-induced im-
munosuppression is thought to play an important role in photo-
carcinogenesis. Thus, a sunscreen that a¡orded protection from
erythema without comparable protection from immunosuppres-
sion could enhance skin cancer risk.
Concern about sunscreens’ability to inhibit UVR-induced im-
munosuppression has resulted in four human studies published in
the Journal of Investigative Dermatology in 2003. These studies
have assessed the capacity of sunscreens to inhibit UVR-induced
suppression of either the induction arm or the elicitation arm of
the contact hypersensitivity (CHS) response. In particular, all stu-
dies address the role of UVA in immunosuppression by asking
the question: Are broad-spectrum sunscreens necessary to ensure
comparable protection against erythema and immunosuppres-
sion? The principle behind the studies is to compare SPF with
immune protection factor (IPF) with the same SSR source using
an SSR dose-response approach. In theory, IPF¼ SPF (i.e. IPF/
SPF¼1) if erythema and immunosuppression share a common
chromophore(s) and both endpoints have dose-response curves
with similar shapes that gives rise to similar action spectra.
In the most recently published study in this issue, Baron et al
(2003) have determined the IPF of two sunscreens with labelled
SPFs of 15. One was primarily a UVB product with a UVA pro-
tection factor (UVA-PF) of 2 whilst the other was a broad-
spectrum sunscreen with a UVA-PF of 10. SPFs reported by the
authors were 15.5 and 18.8 respectively, though lower values of 9.9
and 15.4 respectively were obtained on the study volunteers. IPF
was determined by the ability of the sunscreens to inhibit SSR-
induced suppression of the induction arm of the local CHS re-
sponse using two readouts. Depending on the readout, the IPF
of the UVB sunscreen was 11 or 15 (IPF/SPF¼ 0.7 to 1.5 depend-
ing on SPF and readout) whereas the IPF of the broad-spectrum
product was 37 or 50 (IPF/SPF¼ 2.0 to 3.2 depending on SPF and
readout). The data from the UVB sunscreen suggest that erythe-
ma and immunosupression share a common chromophore/action
spectrum but, in contrast, the data from the broad-spectrum
study suggest that UVA is much more immunosuppressive than
it is erythemogenic. In other words, the action spectra for erythe-
ma and immunosuppression are very di¡erent. A possible expla-
nation for these di¡erent conclusions is that higher dose UVA, as
with the UVB sunscreen, enhances UVB-induced immunosup-
pression. Either way, the implication of this study is that there is a
major, as yet unidenti¢ed, UVA chromophore(s) that plays a role
in immunosuppression. However, in practice these data also sug-
gest that UVB sunscreens give adequate immunoprotection (IPF/
SPF¼1), unless better immunoprotection than sunburn protec-
tion is considered bene¢cial. This is debatable because some im-
munosuppression may be desirable to prevent hypersensitivity
reactions to photoantigens that may initiate photodermatoses
such as polymorphic light eruption (van de Pas et al, in press).
Baron et al (2003) used a study design that was essentially simi-
lar to those of Wolf et al (2003) and Kelly et al (2003).Wolf et al
(2003) compared a UVB with a broad-spectrum sunscreen with
SPFs of 5.2 and 6.2 respectively.The IPF was similar to the SPF of
the UVB sunscreen (IPF/SPF¼ 0.9^1.1 depending on readout/
analysis) but higher than the SPF of the broad-spectrum product
(IPF/SPF¼1.2^1.8). However, the IPF/SPFs of the two products
were not signi¢cantly di¡erent. Kelly et al (2003) studied a single
primarily UVB sunscreen and found the IPF to be less that 50%
of its SPF (IPF/SPF¼ 0.4). It is very di⁄cult to reach a clear over-
all conclusion from these three studies. On the one hand, it could
be argued that they support a mechanistic role for UVA in im-
munosuppression because the conclusions/speculations of their
respective authors are qualitatively similar but it is clear that there
are major quantitative di¡erences in the results that are rather dif-
¢cult to explain. On the other hand, only the study of Kelly et al
(2003) suggests that broad-spectrum sunscreens are necessary to
ensure that IPF/SPF¼1. It should be noted that these studies have
used di¡erent skin type populations, readouts and/or methods of
raw data processing and all studies used complex and di¡erent
statistical analyses (each paper has statistician co-authorship). At
present the authors are discussing a ‘‘meta-analysis’’ in which
comparative analyses will be done with similar readouts/raw
data processing and it will be interesting to see if the di¡erences
in the results are due to any bias from data collection and
analysis. This question has been approached to some extent by
Wolf et al (2003) who reached similar conclusions with di¡erent
readouts.
It is noteworthy that Baron et al (2003) and Wolf et al (2003)
have con¢rmed Kelly and colleagues (2003) observation that a
single sub-erythemal SSR exposure is immunosuppressive. This
implies that signi¢cant immunosuppression may occur even if a
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sunscreen is used to prevent sunburn. In other words, erythema is
not a useful bio-marker for immunosuppression, and this may
also apply to cancer risk. One must also add that these lengthy
and di⁄cult studies have assessed the e¡ect of a single SSR
exposure. The important issue, yet to be addressed, is the role of
sunscreens in routine use.
Poon et al (2003) assessed the ability of 6 sunscreens (SPFs from
6^20) to inhibit SSR-induced local suppression of the elicitation
arm of the CHS response after four daily SSR exposures. Analy-
sis was based on pooled data from 15 volunteers per sunscreen.
These authors reported that IPF was not correlated with SPF
but was positively correlated with UVA-PF (ranging from
1.6^4.7).With 4 sunscreens IPF/SPF was greater than/equal to 0.9,
with 1 IPF/SPF¼ 0.7 and with 1 IPF/SPF¼ 0.2. Overall, these
data suggest adequate immunoprotection (i.e. IPF/SPF¼1), even
with UVA-PFs of 2^3 in some cases.The conclusions of Poon et al
(2003), that UVA plays a mechanistic role in immunosuppression,
support those published in the Journal of Investigative Dermatol-
ogy by Moyal and Fourtanier (2001) using suppression of the eli-
citation arm of the delayed type hypersensitivity reaction to a
battery of recall antigens.
It is worth stating that immunosuppression studies in mouse
and man with UVA alone have given mixed results and some stu-
dies, albeit with di¡erent protocols, suggest that UVA may abro-
gate UVB-induced immunosuppression (Reeve andTyrrell, 1999;
Garssen et al, 2001). Spectral interaction has also been reported in
humans (Kuchel et al, 2002) in whom UVA enhanced SSR-in-
duced suppression of the elicitation arm of the CHS response.
Such experiments may mean that interpretations based on action
spectra are redundant unless the action spectra for the interactions
are known. In the end it may all boil down to ‘‘spectral balance’’
whereby relatively modest di¡erences in the spectral pro¢le of
UVR that reaches the skin through the sunscreen could make
disproportionately large di¡erences to biological outcome.
Baron et al (2003),Wolf et al (2003) and Kelly et al (2003) used
many volunteers because studies on the suppression of the induc-
tion arm of the CHS response are based on a single sensitisation
step. Clearly, large groups are not practicable or a¡ordable for
routine IPF assessment. Studies on the suppression of the elicita-
tion arm of the CHS response require relatively few volunteers
because multiple exposure sites per volunteer are possible. How-
ever, the latter approach seems to require repeated SSR exposure
so a direct comparison between IPF and SPF, based on a single
exposure, is not possible.
Apart from the practical issues, there is the vital question of
biological signi¢cance of immunoprotection. Suppression of the
induction and elicitation arms of the CHS response must surely
occur by di¡erent mechanisms, possibly via common chromo-
phores. Mouse data suggest that it is the suppression of the induc-
tion arm that is important in skin cancer. However, one could
argue that suppression of the elicitation arm is also important
but this requires study. Finally, there is evidence that the consu-
mer has yet to come to grips with the concept of SPF. Thus, it
may not be useful to add another rather specialised protection in-
dex. Rather, it might be wiser to rede¢ne SPF such that the bio-
logical consequences of a given erythemal dose (even if sub-
erythemal) were not detrimentally modi¢ed by a sunscreen. The
simplest approach would be to opt for neutral density sunscreens.
The assessment of IPF is a di⁄cult task because it raises major
practical, biological, data management and statistical issues that
were discussed in Paris in July 2002 by the 5 groups whose Jour-
nal of Investigative Dermatology papers are referred to in this
commentary. This discussion has resulted in a consensus paper
that is in preparation. It is hoped that this document will ulti-
mately lead to a standard, meaningful and routinely a¡ordable
method of IPF assessment.
REFERENCES
Baron ED, Fourtanier A, Compan D, Medaisko C, Cooper KD, Stevens SR: High
UVA protection a¡ords greater immune protection con¢rming that UVA con-
tributes to photoimmunosuppression in humans. J Invest Dermatol 121:869^875,
2003
IARC Handbooks of Cancer Prevention. Sunscreens vol 5. Lyon, WHO International
Agency for Research on Cancer, 2001
Garssen J, de Gruijl F, Mol D, de Klerk A, Roholl P, van Lovern H: UVA exposure
a¡ects UVB and cis-urocanic acid-induced systemic suppression of immune
responses in Listeria monocytogenes-infected Balb/c mice. Photochem Photobiol
73:432^438, 2001
Kelly DA, Seed PT, Young AR, Walker SL: A commercial sunscreen’s protection
against ultraviolet radiation induced immunosuppression is more than 50%
lower than protection against sunburn in humans. J Invest Dermatol 120:65^71,
2003
Kuchel JM, Barnetson R StC, Halliday GM: Ultraviolet A augments solar-simulated
ultraviolet radiation-induced local suppression of recall responses in humans.
J Invest Dermatol 118:1032^1037, 2002
Moyal D, Fourtanier AM: Broad-spectrum sunscreens provide better protection
from the suppression of the elicitation phase of delayed-type hypersensitivity
response in humans. J Invest Dermatol 117:1186^1192, 2001
Poon SC, Barnetson R StC, Halliday GM: Prevention of immunosuppression by
sunscreens in humans is unrelated to protection from erythema and dependent
on protection from ultraviolet A in the face of constant UVB protection.
J Invest Dermatol 121:184^190, 2003
Reeve VE,Tyrell RM: Heme oxygenase induction mediates the photoimmunopro-
tective activity of UVA radiation in the mouse. Proc Natl Acad Sci USA
96:9317^9321, 1999
van de Pas C, Seed P, Hawk J,Young AR,Walker SL: UVR-induced suppression of
contact hypersensitivity responses in patients with polymorphic light eruption.
J Invest Dermatol, in press
Wolf P, Ho¡man C, Quehenberger F, Grinschgl S, Kerl H: Immune protection fac-
tors of chemical sunscreens measured in the local contact hypersensitivity
model in humans. J Invest Dermatol, in press
x YOUNG THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
